Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy
- 19 March 2003
- journal article
- Published by Elsevier
- Vol. 288 (2) , 201-207
- https://doi.org/10.1016/0922-4106(95)90195-7
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- COMPARATIVE STUDY ON α1‐ADRENOCEPTOR ANTAGONIST BINDING IN HUMAN PROSTATE AND AORTAClinical and Experimental Pharmacology and Physiology, 1994
- Alpha‐blocking Treatment with Alfuzosin in Symptomatic Benign Prostatic Hyperplasia: Comparative Study with PrazosinBritish Journal of Urology, 1993
- AlfuzosinDrugs, 1993
- Doxazosin Treatment in Patients with Prostatic ObstructionScandinavian Journal of Urology and Nephrology, 1993
- Pharmacokinetics of alfuzosin after single oral administration to healthy volunteers, of three different dosesBiopharmaceutics & Drug Disposition, 1992
- Is Indoramin an Effective Alternative to Prostatectomy?British Journal of Urology, 1992
- Alfuzosin for benign prostatic hypertrophyThe Lancet, 1991
- Molecular cloning and sequencing of a cDNA encoding a human α1A adrenergic receptorBiochemical and Biophysical Research Communications, 1991
- Alfuzosin for treatment of benign prostatic hypertrophyThe Lancet, 1991
- A Placebo‐controlled Double‐blind Study of the Effect of Phenoxybenzamine in Benign Prostatic ObstructionBritish Journal of Urology, 1978